Peds-ONC Immunotherapy Center:
Enhancing Antigen and Cytokine Expression to Break Immune Tolerance

Cassady KA, Lee DA, Cairo MS, Roberts RD, Behbehani, GK, Wang R, Mo, X, Mardis ER, Cripe TP

Divisions of Infectious Diseases and Pediatric Hematology/Oncology/BMT, Nationwide Children’s Hospital; Center for Childhood Cancer and Blood Diseases, Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children’s Hospital; Division of Hematology, Center for Biostatistics, The Ohio State University; Cancer and Blood Diseases Center, Department of Pediatrics, New York Medical College

Abstract
Gliomas, like other solid tumors, restrict immune recognition of aberrant cancer cells. Further complicating this, pediatric cancers also have lower mutation rates than adult tumors making them more difficult to generate an immunotherapeutic response. This proposal addresses three mechanisms contributing to immune resistance in pediatric tumors: 1) low mutational burden, 2) evasion immunosuppressive environment, and 3) MHC downregulation (immuno-editing). We have developed a multimodal virus-based vaccine platform that uses the virus’s natural ability to recruit immune cells and break immune tolerance to improve immune activity against the tumor. By encoding tumor associated self-antigens within the viral genome so that they are expressed during infection our results show that we can convert the antiviral response into an anti-tumor response. The studies described in this proposal seek to improve our virus-based multi-modal vaccine approach to overcome immune restriction in one of the most difficult to treat solid tumors, malignant glioma.

Hypothesis
Engineered viral modifications that enhance native and adoptive immune cell activity will improve durable anti-tumor activity in treatment-resistant pediatric gliomas

Background
Fig 1 C134 is a next generation virus that evades translational arrest and stimulates early IFN and chemokine signaling (Cassady 2017). In some tumor models, onHSV treatment stimulates tumor specific T cells that recognize and suppress tumor growth after virus infection has resolved (Ghoneime and Cassady, CUR, 2018). Other tumors however are less responsive and OV therapy induces an antiviral rather than tumor specific response. Pediatric Tumors have low mutational loads and are less immune responsive. Improving virotherapeutic response in cold tumors

Aim 1 OVERVIEW
AIM 1: Improve the Immune-Mediated Anti-Tumor Response Through Virus-based Tumor Associated Antigen Expression

Fig 2 OV-based tumor associated antigen (TAA) expression improves anti-tumor activity and overall survival in an immunotherapy resistant EphA2 (+) C57BL/6 based glioma

Fig 3 C170-treated mice suppress tumor growth on re-challenge and possess circulating CTLs with EphA2 functional response (Granzyme B production and CD25 upregulation shown after peptide pulsing)

Aim 1 studies will
• Determine how tumor associated EphA2 antigen and MHC-I expression impacts C170 efficacy
• Evaluate whether C170 treatment induces epitope spread
• Delineate predictive immune markers of C170 anti-tumor response using CyTOF

Aim 2 OVERVIEW
AIM 2: Promote antigen presentation and a durable anti-tumor immune response

Fig 4 Myeloid targeting domains incorporated in the virus expressed antigen improve anti-tumor immune activity and suppresses tumor growth on re-challenge.

Aim 2 studies will:
• Delineate how myeloid targeted TAs enhance the anti-tumor immune response
• Improve anti-tumor T cell response by incorporating antigen presenting cell targeting domains in the TAs for myeloid rich tumors
• Suppress tumor associated myeloid populations to improve the immune mediated T cell anti-tumor activity (in collaboration with Dr. Cripe)

Aim 3 OVERVIEW
AIM 3: Enhance antitumor activity by improving cytokine/cell therapy recruitment and activity

Fig 6 Phase I clinical studies show that antiviral Type 1 IFN and adoptive immune cell responses correlate with OV-mediated survival. Immunoedited tumors (e.g. MHC I downregulated) may suppress virus-TAA therapy. We postulate that onHSV cytokine & chemokine expression in combination with adoptive cellular therapy will overcome these restrictions.

Aim 3 studies will:
• Evaluate OV-based cytokine and chemokine effect with native immune cell activity
• Improve adoptive cellular therapy (NK and CAR-NK) recruitment and anti-tumor activity using onHSV-based chemokine and cytokine expression (in collaboration with Dr. Lee and Dr. Cairo)

Impact
If successful, this flexible multimodal viral vaccine platform will harness and direct both native and adoptive cellular therapeutics against low mutational load immunotherapy-resistant tumors

Acknowledgements
Funded in part by the National Cancer Institute Cancer Moonshot US4-CA22561-01A1, Alex’s Lemonade Stand Foundation, and Cure4Cam Childhood Cancer Foundation. In full disclosure, C134 is in license agreement with Mustang Bio